Nautilus Biotech Announces Progress on Improved Interferon Beta for Multiple Sclerosis
01-Mar-2004 -
PARIS, France. Nautilus Biotech today announced that it
has developed enhanced IFNbeta molecules, engineered to have a substantially
increased half-life.
The novel molecules, developed using Nautilus' proprietary technology for
protein evolution, show significantly higher levels of stability in ...
multiple sclerosis
mutagenesis
PEGylation
+1